Receive engineered immune cells designed to fight advanced HER2-positive cancers

Back to Metastatic Gastric Cancer trials

Recruiting

What is this trial?

This trial is testing a new cancer treatment called , which uses your own immune cells that doctors engineer in the laboratory to recognize and attack cancer cells. The study focuses on advanced cancers that express a protein called HER2, including breast, gastric, and endometrial cancers. Researchers want to see if this treatment is safe and how well it works against these cancers.

Many patients with HER2-positive advanced cancers have limited treatment options, especially after standard therapies stop working. This medication is being developed to offer a new approach by harnessing your body's own immune system to specifically target cancer cells that have the HER2 protein.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with advanced or metastatic HER2-positive breast, gastric, endometrial, or other solid tumors that cannot be surgically removed
your cancer has either stopped responding to standard treatments or you are unable to receive standard therapy
you have adequate organ function (normal blood counts, liver and kidney function) as confirmed by recent blood tests
you have good overall health and are able to care for yourself with minimal assistance (ECOG performance status 0 or 1)
you are not infected with HIV, hepatitis B, or hepatitis C

You likely don't qualify if…

you have active hepatitis B or C infection
you have HIV infection
your blood counts, liver function, or kidney function are too low
you are pregnant or breastfeeding
you cannot commit to the study schedule and follow-up visits over 3–4 years

What participation looks like

You will first undergo chemotherapy for 3 days to prepare your immune system. A few days later, you will receive an infusion of your engineered immune cells through an IV. You'll stay under close medical supervision during and after the infusion, with frequent visits to monitor for side effects and how well the treatment is working. The study lasts 3–4 years, with most intensive monitoring in the first few months after treatment.

Testing engineered immune cells to fight advanced HER2-positive cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)